Vaxart Inc (VXRT)

$0.32 0.00 (N/A)
Market Cap 97.49M
Revenue (ttm) 28.70M
Net Income (ttm) -66.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -233.28%
Debt to Equity Ratio 0.00
Volume 11,568,300
Avg Vol 5,416,006
Day's Range N/A - N/A
Shares Out 228.31M
Stochastic %K 7%
Beta 1.14
Analysts Strong Sell
Price Target $4.67

Company Profile

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influ...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 550 3500
Fax: 650 871 8580
Website: vaxart.com
Address:
170 Harbor Way, Suite 300, South San Francisco, United States
JF42
JF42 Aug. 21 at 6:44 AM
$VXRT webcast can be listened to on their webapge https://investors.vaxart.com/events/event-details/vaxart-inc-stockholder-fireside-chat it requires you to fill in information, I preffer not to use my data, so fill in something and when it asks for code, enter Vaxart2025
0 · Reply
1BudgetTrader
1BudgetTrader Aug. 21 at 4:57 AM
$VXRT NO, on so many different levels. Seemed like Lo was kinda giddy when he explained the June 13 disaster. We were glad to have the cash. We signed the base contract almost 1.5 months before, but these dilution deals take time, so we couldn't let anyone know until that was secured, which just so happened to be on the same date as funding. Sean needs a fire lit under his ass. Anyone remember the 100 day challenge. But here we are, 150 days after announcing we were conducting pre clinical studies, and we still don't know results... wtf. He also needs to learn time management, did he really say they used the June 13 money to improve the NextGen constructs. Did they pull the P2b outta their asses a week before the trial started. WHY are they working on HPV if they're desparate for money? James just seemed to be frustrated, I think he needs to get laid or something. I thought I heard a voice in my head screaming "Nobody can be this stupid" while I listened, sounded like Lo.
1 · Reply
Chalutz
Chalutz Aug. 21 at 4:42 AM
$VXRT If 15 biotech hedge funds started slowing accumulating 5 million shares each at these levels their avg price would be < 50 cents giving them 75 Million shares. Then get more aggressive and each put in a bid for 4 million shares at $1. This keeps them below threshold 9+ million shares. 15 hedge funds own 135 million shares more than 50% of Co at avg of 75 cents a shares or 150 million mkt of a co with $450+ mill govt funding. They dispose of BOD, Lo and greedy, shameless incompetent mgmt. Co easily regains NASDAQ COMPLIANCE and no RS as HFs not going to screw themselves. They institute a share buyback program Instead. Tough stuff . Potential grand slam for HFs getting in at these levels for co with unlimited upside. FN layup.
2 · Reply
Player2021
Player2021 Aug. 21 at 4:35 AM
$VXRT Having spared myself the grief by not listening in on the Lo chat, I gather from all the posts here that it very much appears they know the rs is once again expected to be voted down. That to me makes the chat worthwhile! I’m in it to the end or hopefully to a new beginning!! I gotta say, this is the most expensive ring side seat to a circus that I’ve ever purchased, though!!
0 · Reply
LyonTeeth
LyonTeeth Aug. 21 at 4:20 AM
$VXRT Who is up watching this thing?
0 · Reply
khalihhhh
khalihhhh Aug. 21 at 4:05 AM
$VXRT They have the science and will eventually prevail. We will wait, we are fine here in OTC, as long as it takes to get the needle moving organically. The bottom line: NO R/S. The vote is definitely NO
0 · Reply
Hajile
Hajile Aug. 21 at 4:04 AM
$VXRT Lo is a Patsy. Cut off the head of the snake, Finney. Shareholders don't have a say in ceo. We have a say with bod who chooses CEO's.
0 · Reply
LesterG
LesterG Aug. 21 at 3:50 AM
$VXRT someone stop this scam before it’s too late. submit more SEC complaints lol
1 · Reply
TimLimb
TimLimb Aug. 21 at 3:47 AM
$VXRT Do we have a recording of the call? Any shareholder protection things being discussed? Like revoking voting rights on preferred shares and add a max cap of 10M authorized shares increase to the charter? Reading the comments here makes me think that they A. didn't say anything new which would change our minds. And B didn't take any actions towards protecting retail investments post split. But I haven't listened to the call yet. Maybe they will dazzle me.
2 · Reply
LesterG
LesterG Aug. 21 at 3:37 AM
$VXRT pretty insane they are willing to risk solvency over rewarding their own shareholders. Vaxart will go down as one of the largest scams in stock market history
1 · Reply
Latest News on VXRT
Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 9:01 PM EDT - 7 days ago

Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript

US orders Vaxart to stop COVID-19 trial amid mRNA wind down

Aug 13, 2025, 5:25 PM EDT - 7 days ago

US orders Vaxart to stop COVID-19 trial amid mRNA wind down

Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq

Jul 24, 2025, 4:01 PM EDT - 27 days ago

Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

Jun 13, 2025, 4:52 PM EDT - 2 months ago

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

Jun 11, 2025, 7:30 AM EDT - 2 months ago

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

Jun 10, 2025, 4:47 PM EDT - 2 months ago

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

Vaxart Announces Adjournment of Annual Meeting of Stockholders

Jun 2, 2025, 4:20 PM EDT - 2 months ago

Vaxart Announces Adjournment of Annual Meeting of Stockholders

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

May 29, 2025, 4:05 PM EDT - 2 months ago

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders

May 29, 2025, 8:00 AM EDT - 2 months ago

Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

May 28, 2025, 8:00 AM EDT - 3 months ago

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 27, 2025, 8:00 AM EDT - 3 months ago

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 20, 2025, 5:00 PM EDT - 3 months ago

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting

May 16, 2025, 8:00 AM EDT - 3 months ago

Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting

Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 15, 2025, 8:00 AM EDT - 3 months ago

Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine

May 14, 2025, 4:05 PM EDT - 3 months ago

Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine

Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript

May 13, 2025, 8:43 PM EDT - 3 months ago

Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript

Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 4:05 PM EDT - 3 months ago

Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

Vaxart Appoints Jeroen Grasman as Chief Financial Officer

May 13, 2025, 4:01 PM EDT - 3 months ago

Vaxart Appoints Jeroen Grasman as Chief Financial Officer

Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement

May 12, 2025, 8:00 AM EDT - 3 months ago

Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement

Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress

May 5, 2025, 8:00 AM EDT - 3 months ago

Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress

Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13

May 2, 2025, 8:00 AM EDT - 3 months ago

Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

Apr 30, 2025, 8:00 AM EDT - 4 months ago

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

Vaxart to Present at World Vaccine Congress Washington 2025 on April 23

Apr 16, 2025, 8:00 AM EDT - 4 months ago

Vaxart to Present at World Vaccine Congress Washington 2025 on April 23

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23

Apr 16, 2025, 8:00 AM EDT - 4 months ago

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23

Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 6:25 PM EDT - 5 months ago

Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Mar 20, 2025, 4:01 PM EDT - 5 months ago

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Mar 11, 2025, 8:00 AM EDT - 5 months ago

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

Mar 5, 2025, 4:05 PM EST - 6 months ago

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

Jan 13, 2025, 7:55 PM EST - 7 months ago

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Dec 2, 2024, 4:01 PM EST - 9 months ago

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 6:19 PM EST - 10 months ago

Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 4:01 PM EST - 10 months ago

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Sep 30, 2024, 4:12 PM EDT - 11 months ago

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside

Aug 15, 2024, 1:57 PM EDT - 1 year ago

Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside

Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 8:51 PM EDT - 1 year ago

Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8

Aug 2, 2024, 8:00 AM EDT - 1 year ago

Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8

Vaxart Inc: Asymmetric Risk-Reward Opportunity Following BARDA Funding

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Vaxart Inc: Asymmetric Risk-Reward Opportunity Following BARDA Funding

Vaxart Provides Business Update

Jun 17, 2024, 4:05 PM EDT - 1 year ago

Vaxart Provides Business Update

Vaxart Announces $40 Million Underwritten Offering of Common Stock

Jun 13, 2024, 7:07 PM EDT - 1 year ago

Vaxart Announces $40 Million Underwritten Offering of Common Stock

Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Jun 13, 2024, 4:15 PM EDT - 1 year ago

Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript

May 13, 2024, 5:49 PM EDT - 1 year ago

Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript

Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results

May 13, 2024, 4:01 PM EDT - 1 year ago

Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results

Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3

Mar 27, 2024, 8:00 AM EDT - 1 year ago

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3

Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 7:03 PM EDT - 1 year ago

Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

Mar 14, 2024, 4:01 PM EDT - 1 year ago

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14

Mar 7, 2024, 8:00 AM EST - 1 year ago

Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

Mar 6, 2024, 8:00 AM EST - 1 year ago

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

Feb 5, 2024, 8:00 AM EST - 1 year ago

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

JF42
JF42 Aug. 21 at 6:44 AM
$VXRT webcast can be listened to on their webapge https://investors.vaxart.com/events/event-details/vaxart-inc-stockholder-fireside-chat it requires you to fill in information, I preffer not to use my data, so fill in something and when it asks for code, enter Vaxart2025
0 · Reply
1BudgetTrader
1BudgetTrader Aug. 21 at 4:57 AM
$VXRT NO, on so many different levels. Seemed like Lo was kinda giddy when he explained the June 13 disaster. We were glad to have the cash. We signed the base contract almost 1.5 months before, but these dilution deals take time, so we couldn't let anyone know until that was secured, which just so happened to be on the same date as funding. Sean needs a fire lit under his ass. Anyone remember the 100 day challenge. But here we are, 150 days after announcing we were conducting pre clinical studies, and we still don't know results... wtf. He also needs to learn time management, did he really say they used the June 13 money to improve the NextGen constructs. Did they pull the P2b outta their asses a week before the trial started. WHY are they working on HPV if they're desparate for money? James just seemed to be frustrated, I think he needs to get laid or something. I thought I heard a voice in my head screaming "Nobody can be this stupid" while I listened, sounded like Lo.
1 · Reply
Chalutz
Chalutz Aug. 21 at 4:42 AM
$VXRT If 15 biotech hedge funds started slowing accumulating 5 million shares each at these levels their avg price would be < 50 cents giving them 75 Million shares. Then get more aggressive and each put in a bid for 4 million shares at $1. This keeps them below threshold 9+ million shares. 15 hedge funds own 135 million shares more than 50% of Co at avg of 75 cents a shares or 150 million mkt of a co with $450+ mill govt funding. They dispose of BOD, Lo and greedy, shameless incompetent mgmt. Co easily regains NASDAQ COMPLIANCE and no RS as HFs not going to screw themselves. They institute a share buyback program Instead. Tough stuff . Potential grand slam for HFs getting in at these levels for co with unlimited upside. FN layup.
2 · Reply
Player2021
Player2021 Aug. 21 at 4:35 AM
$VXRT Having spared myself the grief by not listening in on the Lo chat, I gather from all the posts here that it very much appears they know the rs is once again expected to be voted down. That to me makes the chat worthwhile! I’m in it to the end or hopefully to a new beginning!! I gotta say, this is the most expensive ring side seat to a circus that I’ve ever purchased, though!!
0 · Reply
LyonTeeth
LyonTeeth Aug. 21 at 4:20 AM
$VXRT Who is up watching this thing?
0 · Reply
khalihhhh
khalihhhh Aug. 21 at 4:05 AM
$VXRT They have the science and will eventually prevail. We will wait, we are fine here in OTC, as long as it takes to get the needle moving organically. The bottom line: NO R/S. The vote is definitely NO
0 · Reply
Hajile
Hajile Aug. 21 at 4:04 AM
$VXRT Lo is a Patsy. Cut off the head of the snake, Finney. Shareholders don't have a say in ceo. We have a say with bod who chooses CEO's.
0 · Reply
LesterG
LesterG Aug. 21 at 3:50 AM
$VXRT someone stop this scam before it’s too late. submit more SEC complaints lol
1 · Reply
TimLimb
TimLimb Aug. 21 at 3:47 AM
$VXRT Do we have a recording of the call? Any shareholder protection things being discussed? Like revoking voting rights on preferred shares and add a max cap of 10M authorized shares increase to the charter? Reading the comments here makes me think that they A. didn't say anything new which would change our minds. And B didn't take any actions towards protecting retail investments post split. But I haven't listened to the call yet. Maybe they will dazzle me.
2 · Reply
LesterG
LesterG Aug. 21 at 3:37 AM
$VXRT pretty insane they are willing to risk solvency over rewarding their own shareholders. Vaxart will go down as one of the largest scams in stock market history
1 · Reply
drunken_Irishman
drunken_Irishman Aug. 21 at 3:10 AM
$VXRT 🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣
1 · Reply
nowiseegood
nowiseegood Aug. 21 at 3:05 AM
$VXRT Coffee guy, joined in August 2025, 2 followers. "Please sell your shares".
1 · Reply
notrap1792
notrap1792 Aug. 21 at 3:01 AM
$VXRT Did Lo say during the fire sale chat that he is the most impatient person in the room? 🤡
0 · Reply
Imgoingtoplay
Imgoingtoplay Aug. 21 at 3:01 AM
$VXRT i know we talk about avian flu but why does nobody want to talk about our universal flu or seasonal? JnJ collab went nowhere but there’s no entity in the world that wants to dabble with it? Was the challenge results for flu not accurate? Is vaxart being black balled from big pharma? Make it make sense. I feel like I could call the saudis and ink a deal right now.
1 · Reply
nowiseegood
nowiseegood Aug. 21 at 2:53 AM
$VXRT "Chat" connotes a cordial interaction, an exchange of viewpoints. Today's controlled presentation doesn't fit that description. Just another example of their deception and dishonesty.
1 · Reply
Coffee_black
Coffee_black Aug. 21 at 2:52 AM
$VXRT I feel sorry for that guy who always wrote those long forums of information with a song title at the the beginning. What a waste of time.
1 · Reply
greenday88
greenday88 Aug. 21 at 2:40 AM
$VXRT so after the townhall are we in a better place ? but i see from almost down 10% we are only down 1.36% EOD thats a good come back !
1 · Reply
YetAnotherInvestor
YetAnotherInvestor Aug. 21 at 2:35 AM
$VXRT my vote is not based on what is needed for vaxart to suceed but whether it will succeed under the current management to atleast break even. i do not believe it will under this leadership.
0 · Reply
LesterG
LesterG Aug. 21 at 2:31 AM
$VXRT buyer under 20 cents
4 · Reply
Mi113r7im3XD
Mi113r7im3XD Aug. 21 at 2:27 AM
$VXRT essentially you invest here and you just lose all of your money. While the board “searches for partnerships” Complete fucking embarrassment of a company.
0 · Reply
YetAnotherInvestor
YetAnotherInvestor Aug. 21 at 2:26 AM
$VXRT done with voting on all account now.
0 · Reply
TripleLinde
TripleLinde Aug. 21 at 2:10 AM
$VXRT I missed the call today because of a travel SNAFU (thank you again American Airlines) But reading through the ST board + transcript, I saved myself some angst. We're going to get this done, vote no and hang in there. Vaxart has the science and will ultimately prevail. https://www.zonebourse.com/cours/action/VAXART-INC-40834288/actualite/Transcript-Vaxart-Inc-Shareholder-Analyst-Call-50890006/
1 · Reply